Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -6.72% | -7.27% | -11.24% | 5.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -6.72% | -7.27% | -11.24% | 5.45% |
| Cost of Revenue | -- | 16.74% | 5.69% | 17.20% | -- |
| Gross Profit | -- | -18.46% | -12.48% | -20.51% | -- |
| SG&A Expenses | -- | -2.00% | -37.45% | 18.66% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 4.36% | -22.97% | 18.12% | 2.55% |
| Operating Income | -- | -602.88% | 84.34% | -74.12% | 19.77% |
| Income Before Tax | -- | -108.66% | -202.93% | -386.40% | -- |
| Income Tax Expenses | -- | 19.13% | 5.47% | -108.33% | -- |
| Earnings from Continuing Operations | -- | -128.00% | -240.79% | -855.16% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -119.84% | -247.26% | 67.69% | -- |
| Net Income | -- | -124.85% | -262.22% | -515.75% | -1,149.62% |
| EBIT | -- | -602.88% | 84.34% | -74.12% | 19.77% |
| EBITDA | -- | -238.49% | 56.01% | -73.20% | 9.69% |
| EPS Basic | 97.78% | -125.00% | -263.64% | -560.00% | -1,138.46% |
| Normalized Basic EPS | -- | -233.33% | -241.67% | -475.00% | -- |
| EPS Diluted | 97.78% | -125.00% | -263.64% | -560.00% | -1,138.46% |
| Normalized Diluted EPS | -- | -233.33% | -241.67% | -475.00% | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |